p53MVA therapy in patients with refractory gastrointestinal malignancies elevates p53-specific CD8+ T-cell responses.

@article{Hardwick2014p53MVATI,
  title={p53MVA therapy in patients with refractory gastrointestinal malignancies elevates p53-specific CD8+ T-cell responses.},
  author={Nicola R. Hardwick and Mary Carroll and Teodora I Kaltcheva and Dajun Qian and Dean W. Lim and Lucille Leong and Peiguo G. Chu and Joseph Kichul Kim and Joseph Chao and Marwan G. Fakih and Yun Yen and Jonathan Espenschied and Joshua D I Ellenhorn and Don J Diamond and Vincent Chung},
  journal={Clinical cancer research : an official journal of the American Association for Cancer Research},
  year={2014},
  volume={20 17},
  pages={4459-70}
}
PURPOSE To conduct a phase I trial of a modified vaccinia Ankara (MVA) vaccine delivering wild-type human p53 (p53MVA) in patients with refractory gastrointestinal cancers. EXPERIMENTAL DESIGN Three patients were vaccinated with 1.0×10(8) plaque-forming unit (pfu) p53MVA followed by nine patients at 5.6×10(8) pfu. Toxicity was classified using the NCI Common Toxicity Criteria and clinical responses were assessed by CT scan. Peripheral blood samples were collected pre- and post-immunization… CONTINUE READING